肺癌质子治疗患者选择:急性食管毒性NTCP模型的更新与内部-外部交叉验证
本研究对已发表的预测肺癌(放)化疗患者≥2级急性食管毒性(AOT)的正常组织并发症概率(NTCP)模型进行外部验证与更新。四中心937例患者中444例(47%)发生≥2级AOT;经内部-外部交叉验证(IECV)去除同时化疗、性别、肿瘤分期并加入总治疗时间(OTT)后,最终模型含平均食管剂量(MOD)与OTT,性能异质性低(I2=0%),乐观校正AUC为0.75。更新模型已纳入国家适应证方案用于质子放疗患者选择。
要点
- 四中心937例肺癌(放)化疗患者中47%发生≥2级急性食管毒性。
- 最终NTCP模型仅含平均食管剂量与总治疗时间两个预测因子。
- 模型跨中心性能异质性低(I2=0%),乐观校正AUC为0.75。
核心结论
- 更新后的急性食管毒性NTCP模型在不同患者队列中表现良好,已纳入国家适应证方案用于肺癌质子放疗患者选择。
研究设计与样本
- 研究纳入四个中心的患者队列,对已发表的预测≥2级急性食管毒性NTCP模型进行外部验证与更新。
- 采用内部-外部交叉验证(IECV)评估跨队列性能异质性,通过增删参数降低异质性,并用岭回归建立最终模型、以自举法进行内部验证。
主要发现
- 937例患者中444例(47%)发生≥2级急性食管毒性。
- 外部验证显示1个队列需重新校准、另1个队列需修订模型,IECV显示原模型跨队列性能存在异质性。
- 为降低异质性,去除同时化疗、性别、肿瘤分期预测因子,加入总治疗时间(OTT)。
- 最终模型含平均食管剂量(MOD)与OTT,所有性能指标的I2为0%,乐观校正AUC为0.75,校准截距为-0.01、斜率为1.26。
关键数值与推荐
- 最终模型预测因子为平均食管剂量(MOD)与总治疗时间(OTT)。
- 最终模型乐观校正AUC为0.75,校准截距-0.01、斜率1.26,所有性能指标I2为0%。
临床怎么用
- 该更新模型已加入国家适应证方案,可用于肺癌患者质子放疗的筛选。
局限性
- 原文未报告模型外部验证的局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To externally validate and update a published normal tissue complication probability (NTCP) model for the prediction of Grade ≥ 2 acute oesophageal toxicity (AOT) in lung cancer patients receiving (chemo-)radiotherapy (predictors: concurrent chemotherapy, gender, tumour stage, mean oesophagus dose (MOD)). METHODS AND MATERIALS: Patient cohorts from four centres were available. Initial external validation was performed by assessing model performance. Heterogeneity of performance across cohorts was evaluated using an internal-external cross validation (IECV) method. Based on the IECV procedure, parameters were added or removed from the model to lower heterogeneity in model performance across cohorts with the aim to create a model that performed uniformly well across centres. Ridge regression was used to create the final model and bootstrapping techniques were applied to perform further internal validation. RESULTS: Out of 937 patients, 444 (47%) had Grade ≥ 2 AOT. External validation indicated model recalibration was necessary for 1 cohort and model revision for another. IECV showed heterogeneity of performance of the original model across cohorts. To lower heterogeneity in model performance, the predictors concurrent chemotherapy, gender, and tumour stage were removed from the model, and overall treatment time (OTT) was added. The final model containing MOD and OTT as predictors showed low levels of heterogeneity in model performance (I2 of 0% for all performance measures) with optimism-corrected AUC of 0.75, calibration intercept of -0.01 and slope of 1.26. CONCLUSION: The validation and updating of an NTCP-model for AOT resulted in a prediction model performing well in varying patient cohorts. Therefore, this updated model was added to the national indication protocol to select lung cancer patients for proton radiotherapy.
引用
- Wijsman R, van Loon JGM, Bartels R, et al. Patient selection for proton therapy in lung cancer: Updating and internal-external cross-validation of a normal tissue complication probability model for acute oesophageal toxicity. Radiother Oncol. 2026. PMID: 42880415. doi:10.1016/j.radonc.2026.111823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。